Last reviewed · How we verify
Queen Elizabeth II Health Sciences Centre — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| oral hypoglycemic agents | oral hypoglycemic agents | marketed | Oral hypoglycemic agents (multiple classes: sulfonylureas, meglitinides, biguanides, thiazolidinediones, DPP-4 inhibitors, GLP-1 agonists, SGLT2 inhibitors) | Diabetes |
Therapeutic area mix
- Diabetes · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Queen Elizabeth II Health Sciences Centre:
- Queen Elizabeth II Health Sciences Centre pipeline updates — RSS
- Queen Elizabeth II Health Sciences Centre pipeline updates — Atom
- Queen Elizabeth II Health Sciences Centre pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Queen Elizabeth II Health Sciences Centre — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/queen-elizabeth-ii-health-sciences-centre. Accessed 2026-05-17.